Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib

Graft-versus-host disease (GVHD) represents a major hurdle impeding the efficacy of allogeneic bone marrow transplantation (BMT). Bortezomib is a proteasome inhibitor that was recently approved for treatment of myeloma. We found that bortezomib potently inhibited in vitro mixed lymphocyte responses...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Proc Natl Acad Sci U S A
Главные авторы: Sun, Kai, Welniak, Lisbeth A., Panoskaltsis-Mortari, Angela, O'Shaughnessy, Matthew J., Liu, Haiyan, Barao, Isabel, Riordan, William, Sitcheran, Raquel, Wysocki, Christian, Serody, Jonathan S., Blazar, Bruce R., Sayers, Thomas J., Murphy, William J.
Формат: Artigo
Язык:Inglês
Опубликовано: National Academy of Sciences 2004
Предметы:
Biological Sciences
Online-ссылка:https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC419567/
https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/15148407/
https://ncbi.nlm.nih.govhttps://doi.org/10.1073/pnas.0401563101
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы